Changes in the use profile of Mectizan: 1987-1997.

  • K. R. Brown
  • Published 1998 in Annals of tropical medicine and parasitology


The usually conservative approach of Merck & Co. to drug development became even more so in the Mectizan (ivermectin, MSD) programme because of adverse experiences following 'extra-label' use in Collie dogs and the discovery of a low threshold for acute neurotoxicity in CF-1 mice. Although a very cautious approach and rapid development programme ensued… (More)